Literature DB >> 28210095

Is Elevated Levels of Serum Soluble Receptor for Advanced Glycation End Products Harmful in Cigarette Smokers?

Kailash Prasad1.   

Abstract

Year:  2016        PMID: 28210095      PMCID: PMC5300036          DOI: 10.1055/s-0036-1579691

Source DB:  PubMed          Journal:  Int J Angiol        ISSN: 1061-1711


× No keyword cloud information.
  29 in total

1.  RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides.

Authors:  M A Hofmann; S Drury; C Fu; W Qu; A Taguchi; Y Lu; C Avila; N Kambham; A Bierhaus; P Nawroth; M F Neurath; T Slattery; D Beach; J McClary; M Nagashima; J Morser; D Stern; A M Schmidt
Journal:  Cell       Date:  1999-06-25       Impact factor: 41.582

Review 2.  Role of Advanced Glycation End Products and Its Receptors in the Pathogenesis of Cigarette Smoke-Induced Cardiovascular Disease.

Authors:  Kailash Prasad; Indu Dhar; Gudrun Caspar-Bell
Journal:  Int J Angiol       Date:  2015-06

3.  Serum soluble receptor for advanced glycation end products (sRAGE) is independently associated with cigarette smoking in non-diabetic healthy subjects.

Authors:  Subrata K Biswas; Sonchita R Mudi; Forhadul H Mollah; Angelika Bierhaus; M Iqbal Arslan
Journal:  Diab Vasc Dis Res       Date:  2013-03-21       Impact factor: 3.291

4.  Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB.

Authors:  A Bierhaus; S Schiekofer; M Schwaninger; M Andrassy; P M Humpert; J Chen; M Hong; T Luther; T Henle; I Klöting; M Morcos; M Hofmann; H Tritschler; B Weigle; M Kasper; M Smith; G Perry; A M Schmidt; D M Stern; H U Häring; E Schleicher; P P Nawroth
Journal:  Diabetes       Date:  2001-12       Impact factor: 9.461

5.  Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues.

Authors:  J Brett; A M Schmidt; S D Yan; Y S Zou; E Weidman; D Pinsky; R Nowygrod; M Neeper; C Przysiecki; A Shaw
Journal:  Am J Pathol       Date:  1993-12       Impact factor: 4.307

Review 6.  Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy.

Authors:  Thoralf Wendt; Nozomu Tanji; Jiancheng Guo; Barry I Hudson; Angelika Bierhaus; Ravichandran Ramasamy; Bernd Arnold; Peter P Nawroth; Shi Fang Yan; Vivette D'Agati; Ann Marie Schmidt
Journal:  J Am Soc Nephrol       Date:  2003-05       Impact factor: 10.121

7.  RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice.

Authors:  Loredana G Bucciarelli; Thoralf Wendt; Wu Qu; Yan Lu; Evanthia Lalla; Ling Ling Rong; Mouza T Goova; Bernhard Moser; Thomas Kislinger; Daniel C Lee; Yogita Kashyap; David M Stern; Ann Marie Schmidt
Journal:  Circulation       Date:  2002-11-26       Impact factor: 29.690

8.  Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE).

Authors:  Lana E Hanford; Jan J Enghild; Zuzana Valnickova; Steen V Petersen; Lisa M Schaefer; Todd M Schaefer; Todd A Reinhart; Tim D Oury
Journal:  J Biol Chem       Date:  2004-09-20       Impact factor: 5.157

9.  Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes.

Authors:  Kazuo Nakamura; Sho-ichi Yamagishi; Hisashi Adachi; Yayoi Kurita-Nakamura; Takanori Matsui; Takafumi Yoshida; Tsutomu Imaizumi
Journal:  Mol Med       Date:  2007 Mar-Apr       Impact factor: 6.354

10.  Effect of advanced glycation end products on endotoxin-induced TNF-alpha, IL-1beta and IL-8 in human peripheral blood mononuclear cells.

Authors:  L L Reznikov; J Waksman; T Azam; S H Kim; P Bufler; T Niwa; A Werman; X Zhang; M Pischetsrieder; S Shaldon; C A Dinarello
Journal:  Clin Nephrol       Date:  2004-05       Impact factor: 0.975

View more
  1 in total

Review 1.  The Beneficial Role of Exercise on Treating Alzheimer's Disease by Inhibiting β-Amyloid Peptide.

Authors:  Zi-Xuan Tan; Fang Dong; Lin-Yu Wu; Ya-Shuo Feng; Feng Zhang
Journal:  Mol Neurobiol       Date:  2021-08-20       Impact factor: 5.590

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.